NEUROHUMORAL REGULATION IN HEART FAILURE: PHYSIOLOGICAL AND PATHOLOGICAL CHANGES

Authors

  • Nasirova Shaxlo Shavkatovna,Khudayberdiyeva Mohinur Janonbek kizi Assistant, Department of Physiology, Samarkand State Medical University,Samarkand State Medical University, Faculty of Medicine No. 2, Group 204 Author

Keywords:

heart failure, RAAS, sympathetic nervous system, BNP, aldosterone, vasopressin, myocardial remodeling.

Abstract

This article discusses the physiological and pathological changes of neurohumoral regulation in heart failure. Special attention is given to the role of the sympathetic nervous system, the renin-angiotensin-aldosterone system (RAAS), natriuretic peptides, and vasopressin in the pathogenesis of heart failure. Neurohumoral activation initially acts as a compensatory mechanism; however, chronic activation leads to maladaptive changes, including myocardial remodeling, fluid retention, and hemodynamic deterioration. Modern diagnostic approaches such as BNP and NT-proBNP biomarkers and functional cardiac assessment are also analyzed.

References

1.McMurray J.J.V. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021.

2.Braunwald E. Heart Failure. Journal of Cardiology, 2019.

3.Yusuf S. et al. Neurohormonal mechanisms in heart failure. Circulation, 2020.

4.Guyton A.C., Hall J.E. Textbook of Medical Physiology, 14th ed.

5.Packer M. Neurohormonal activation in chronic heart failure. New England Journal of Medicine, 2018.

6.Ponikowski P. et al. ESC Heart Failure Guidelines, 2021.

7.Lilly L.S. Pathophysiology of Heart Disease, 7th ed.

8.Zipes D.P., Libby P., Bonow R.O., Mann D.L., Tomaselli G.F. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 12th ed. Elsevier, 2022.

9.Francis G.S., Tang W.H.W. Pathophysiology of heart failure and neurohormonal activation. Journal of the American College of Cardiology, 2019.

10.Cohn J.N. The management of chronic heart failure. New England Journal of Medicine, 2001.

11.Swedberg K., Komajda M., Böhm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT study). Lancet, 2010.

12.Felker G.M., Mentz R.J. Diuretics and ultrafiltration in acute decompensated heart failure. New England Journal of Medicine, 2020.

13.Volpe M., Carnovali M., Mastromarino V. Natriuretic peptides in heart failure: diagnostic and prognostic role. European Heart Journal Supplements, 2016.

14.Gheorghiade M., Pang P.S. Acute heart failure syndromes. Journal of the American College of Cardiology, 2009.

15.Jessup M., Brozena S. Heart failure. New England Journal of Medicine, 2003.

16.McDonagh T.A. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2023.

17.Dickstein K., Cohen-Solal A. et al. ESC Guidelines for heart failure management. European Heart Journal, 2008.

18.Pitt B., Zannad F. Mineralocorticoid receptor antagonists in heart failure. New England Journal of Medicine, 1999.

19.Braunwald E. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. New England Journal of Medicine, 2007.

20.Hollenberg S.M. Vasopressin antagonists in heart failure therapy. Circulation, 2006.

Downloads

Published

2026-05-26